Alli (orlistat) is an over-the-counter drug meant for overweight adults who are struggling to shed excess pounds. Orlistat blocks some of the fat that you eat, keeping it from being absorbed by your body. Orlistat is used to aid in weight loss, or to help reduce the risk of regaining weight already lost. This medicine must be used together with a reduced-calorie diet. Orlistat is for use only in adults.
Alli is the reduced-strength, 60-milligram version of orlistat (Xenical), a 120-milligram prescription drug.
Xenical is approved for use by people who have a body mass index (BMI) of 30 or more (obese), as well as people with a BMI of 27 to 29 (overweight) who have other health risk factors such as high blood pressure or diabetes.
Alli is approved for over-the-counter sale — with some exceptions — to overweight adults 18 years and older. Both Alli and Xenical are meant to be used as part of a weight-loss plan that includes a low-calorie, low-fat diet and regular physical activity.
In 2010, the Food and Drug Administration (FDA) published a safety review of orlistat because of rare reports of serious liver injury in people using it. The FDA found no evidence to confirm that orlistat was the cause of the reported liver injuries.
However, Alli and Xenical labels were revised because of the reports. Talk to your doctor immediately if you have signs or symptoms that may indicate liver injury:
Alli promotes weight loss by decreasing the amount of dietary fat absorbed in your intestines.
Lipase, an enzyme found in the digestive tract, helps break down dietary fat into smaller components, so it can be used or stored for energy. Alli inhibits the work of lipase. When you take the drug with a meal, about 30 percent of the fat you consume isn't broken down and is eliminated through bowel movements.
Alli may help you lose weight, but the weight loss will likely be modest — perhaps just a few pounds more than you would lose with diet and exercise alone.
In a 2014 review of clinical trials, researchers assessed the effect of weight-loss pills in studies that were at least one year long. People who ate a calorie-restricted diet, exercised regularly and took Alli lost an average of 5.5 pounds (2.5 kilograms) more in one year than did people who only dieted and exercised.
About half the people taking Alli while following a calorie-restricted diet and increasing physical activity lost 5 percent or more of their body weight within a year. Clinically meaningful weight loss — enough weight loss to begin lowering the risk of cardiovascular disease, diabetes and other diseases — is generally defined as 5 percent or more of body weight.
One 60-milligram Alli pill is taken with a fat-containing meal up to three times a day. Daily fat intake should be distributed over the three main meals and should be no more than 30 percent of total calories. The manufacturer recommends a fat intake of about 15 grams a meal.
If you eat a meal that contains no fat, then you should not take a dose of Alli. If you take Alli with a high-fat meal, you will likely experience more-severe gastrointestinal side effects.
Alli can reduce the absorption of fat-soluble nutrients, including beta carotene and vitamins A, D, E and K. Take a multivitamin at bedtime and at least two hours after your last dose of Alli.
Gastrointestinal side effects are related to undigested fats passing through your digestive system. They generally subside over time and with appropriate use of the medication. These side effects include:
Other possible side effects include:
Talk with your doctor before taking Alli about possible interactions with other medications, particularly if you take medications for any of the following conditions:
You should not use Alli if you:
A weight-loss plan with diet, exercise and drug therapy is generally considered successful if you lose about 1 pound (0.5 grams) a week during the first month and have lost 5 percent or more of the pre-treatment body weight within one year.
If the treatment is successful, you are more likely to keep weight off or lose more weight if you continue with the diet, exercise and drug treatment plan.
Most weight loss with the medication occurs within the first few months. If you have adhered to the diet and exercise plan and have not lost at least 5 percent of your initial body weight within a few months, continuing the medication may be of little benefit.
If you have not lost 5 percent of body weight within a year on the plan, discontinuing the drug would be a reasonable choice. The risks, side effects and cost associated with taking the medication would likely override any potential benefit.
Alli isn't an easy answer to weight loss and is meant only to supplement — not replace — a healthy diet and regular physical activity.
Work with your doctor to evaluate the potential benefits and risks of Alli or any other weight-loss drugs. As a team, you and your doctor can create the most effective weight-loss plan for you.
人々は、体の内部時計を調節するために、メラトニンを使います。予定が毎日の仕事を変える人々で睡眠覚醒循環を調節するために、それが時差ぼけのために使われます。それが、盲人が1昼夜サイクルを確立するのを援助するために使われます。メラトニンが、寝入る(不眠症)ことができないことのためにも、使われます; 遅延性睡眠段階症候群(DSPS); 急速眼球運動睡眠行動障害(RBD); 注意力欠陥-活動亢進障害(ADHD)を伴う不眠症; 特定の高血圧薬物による不眠症は、ベータ受容体遮断薬を呼びました; そして、自閉症、脳性麻痺と知的な障害を含む発達上の障害の子供たちの睡眠問題。ベンゾジアゼピン薬の用法をやめた後に、そして、禁煙する副作用を減らすために、それが睡眠援助としても使われます。一部の人々は、アルツハイマー病または記憶喪失(痴呆)のためにメラトニンを使います。障害、慢性閉塞性肺疾患(COPD)と呼ばれている肺疾患、ベータ受容体遮断薬薬に起因する不眠症、子宮内膜症のために、一部の人々はメラトニンを使います。そして、耳、落ち込みまたは季節性感情障害(SAD)、軽い精神的欠陥、アルコールを含まない肝疾患、慢性疲労症候群(CFS)、線維筋痛、絶え間ない足症候群を取り囲みます。そして、炎症性病気がサルコイドーシス、精神分裂症、片頭痛と他頭痛、年齢に関連する視力損失、良性前立腺過形成(BPH)、過敏性大腸症候群(IBS)、骨損失(骨粗鬆症)、遅行性顔面麻痺(TD)と呼ばれている運動障害と呼ばれています。酸性の逆流病、ヘリコバクターピロリ(H. pylori)、運動パフォーマンス、不妊性、癲癇、手術後の回復、麻酔に起因する動揺、ストレス、不随意運動障害(遅行性顔面麻痺)、定めることから体を起こす(姿勢の心搏急速症候群)ことに、貴社が移る心拍数の変化、精神錯乱、排尿をコントロールすることができないこと、あごの痛み、炎症性腸疾患(潰瘍性大腸炎)のための更年期(メタボリックシンドローム)のために、老化のために、そして、産児制限のために、一部の人々は、メラトニンを使います。 ... 詳細
3mg